全球生物製药和疫苗製造市场规模（按产品类型、技术、应用、区域范围和预测）

生物製药和疫苗製造市场规模和预测

过去几年，生物製药和疫苗製造市场规模以中等速度成长，成长率相当高，预计在预测期内，即 2026-2032 年，市场规模将大幅成长。

生物製药和疫苗生产的全球市场驱动力

生物製药和疫苗製造市场的市场驱动因素可能受到多种因素的影响，其中包括：

感染疾病的增加：肝炎、COVID-19、流感、人类乳突病毒 (HPV) 等感染疾病的盛行率上升，推动了对疫苗和生物製药的需求。在全球范围内，各国政府和医疗保健组织正在优先开展疫苗宣传活动和药物研究倡议，以对抗这些疾病，从而推动市场扩张。

生物製药需求日益增长：生物製药为多种疾病（包括癌症、自体免疫疾病和感染疾病）提供针对性和个人化的治疗方案。这些治疗方法包括单株抗体、重组蛋白、疫苗和细胞疗法。生物製药需求的不断增长正在推动对基础设施和生产能力的投资。

製造流程的技术进步：由于一次性系统、连续生产和自动化等生物加工技术的发展，生物製药和疫苗的生产变得更有效率、可扩展且成本更低。这些技术进步缩短了生产时间，并提高了生产效率，从而推动了生物製药和疫苗的发展。

良好的法规环境已然形成，欧洲药品管理局（EMA）和美国食品药物管理局（FDA）等机构为疫苗和生物製药的生产提供指导和协助。更快捷的核准流程、优惠的法规和奖励，都有助于鼓励对技术和工业设施的投资。

生技的应用不断拓展：疫苗和生物製药的研发、生产和发现都高度依赖生技。基因工程、细胞培养技术和生物资讯学的进步推动并促进了各种疾病的创新治疗方法和疫苗的开发。

全球卫生倡议和疫苗接种计划：预防和控制感染疾病的疫苗接种计划和全球卫生倡议得到了官民合作关係、国际组织和政府倡议的支持，为生物製药和疫苗製造商扩大产品线和进入新市场提供了机会。

疫情防治与因应：像 COVID-19 疫情这样的情况凸显了采取快速应对和防控措施的重要性。为了因应新兴感染疾病的风险，各国政府和医疗机构优先投资于疫苗研发和生产基础设施，这推动了市场需求。

增加研发支出：为了发现和创造新的生物药物和疫苗，製药公司、生技公司和学术机构正在投入大量资源进行研发。创新、产品线开发和产品开发均由研发投资驱动。

人口老化：随着人口老化，人们更容易感染感染疾病和慢性病，疫苗和生物製药的需求也随之增加。随着全球人口老化，治疗和预防生技药品的市场正在不断扩大。

新兴市场：疫苗和生物製药製造业在新兴经济体，尤其是拉丁美洲和亚太地区，拥有巨大的成长潜力。医疗成本的上涨、医疗基础设施的建设以及疾病负担的增加，正在推动这些地区的市场扩张。

限制全球生物製药和疫苗製造市场的因素

生物製药和疫苗製造市场可能面临多种限制和挑战，包括：

高昂的开发和生产成本：生物製药和疫苗的研发、生产设施和设备必须预先购买。高昂的成本可能会阻碍小型公司和新兴企业进入市场，从而降低竞争和创新能力。

复杂的製造步骤：细胞培养、发酵和精製只是用于生产生物製药和疫苗的先进生物技术步骤中的几个步骤。与普通药物相比，这些技术需要专门的工具、知识和品管程序，从而导致更高的生产成本和更长的前置作业时间。

监管要求与合规性：欧洲药品管理局 (EMA) 和美国食品药物管理局(FDA) 等卫生机构对疫苗和生物製药的生产实施严格的监管控制。对于新产品和生产设施而言，满足产品品质、安全性和有效性的监管标准可能既昂贵又耗时。

专利保护和智慧财产权：生物製药和疫苗产业的特点是拥有强大的专利保护和智慧财产权。专利独占期为创新产品提供了市场独占权，并防止学名药和生物相似药竞争对手的竞争。然而，专利到期也会导致品牌产品竞争加剧，价格下降。

供应链脆弱性：疫情、天灾和地缘政治不稳定等事件可能会扰乱生物製药和疫苗生产的全球供应链。供应链中断可能导致关键物资、机械和零件短缺，进而影响产量和产品供应。

市场准入和报销挑战：分销网络、医疗基础设施以及定价和报销政策限制了某些地区生物製药和疫苗的获取。市场进入问题可能会影响创新产品的开发和应用，尤其是在资源匮乏的新兴经济体。

技术复杂性与创新风险：随着精製方法、反应器设计和细胞株开发的突破，用于生产疫苗和生物製药的技术不断变化。投资新技术和创新存在固有风险，包括可扩展性问题、监管不确定性和技术难题。

产品生命週期管理：药物安全检测、产品监管和上市后监管是管理生物製药和免疫产品生命週期所需的持续投资。在产品生命週期中，生产流程、监管要求和产品配方的变更可能需要昂贵的升级和修订。

安全与品质保证：确保生物製药和疫苗的效力、安全性和纯度对公共卫生至关重要。批次测试、验证流程和品管技术对于维护产品品质至关重要。

目录

第一章全球生物製药和疫苗製造市场简介

• 市场概览
• 研究范围
• 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

• 资料探勘
• 验证
• 第一手资料
• 资料来源列表

第四章全球生物製药与疫苗製造市场展望

• 概述
• 市场动态
  • 驱动程式
  • 限制因素
  • 机会
• 波特五力模型
• 价值链分析

第五章全球生物製药和疫苗製造市场（依产品类型）

• 概述
• 疫苗
• 生物製药

6. 全球生物製药和疫苗製造市场（依最终用途）

• 感染疾病
• 肿瘤学
• 自体免疫疾病
• 代谢紊乱

7. 全球生物製药和疫苗製造市场（按技术）

• 上游流程
• 下游工艺
• 一次性使用系统
• 常规製造

8. 全球生物製药和疫苗製造市场（按地区）

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 其他的
  • 拉丁美洲
  • 中东和非洲

第九章全球生物製药与疫苗製造市场：竞争格局

• 概述
• 各公司市场排名
• 重点发展策略

第十章 公司简介

• Novartis
• Pfizer
• Sanofi
• Roche
• Abbott
• Regeneron Pharmaceuticals
• Alexion Pharmaceuticals
• Johnson and Johnson
• GlaxoSmithKline
• Merck

第十一章 附录

• 相关调查

Biopharmaceutical And Vaccine Production Market Size And Forecast

Biopharmaceutical And Vaccine Production Market size is growing at a moderate pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2026 to 2032.

Global Biopharmaceutical And Vaccine Production Market Drivers

The market drivers for the Biopharmaceutical And Vaccine Production Market can be influenced by various factors. These may include:

Growing Incidence of Infectious Diseases: The need for vaccinations and biopharmaceuticals is driven by the rising prevalence of infectious diseases, including hepatitis, COVID-19, influenza, and human papillomavirus (HPV). Globally, governments and healthcare institutions provide priority to immunization campaigns and medication research initiatives in an attempt to combat these illnesses, which drives market expansion.

Growing Need for Biopharmaceuticals: Biopharmaceuticals provide targeted and individualized therapy choices for a range of ailments, including cancer, autoimmune disorders, and infectious diseases. Examples of these treatments include monoclonal antibodies, recombinant proteins, vaccines, and cell therapies. Infrastructure and production capacity are being invested in due to the rising demand for biopharmaceuticals.

Technological Progress in manufacture Processes: The manufacture of biopharmaceuticals and vaccines is becoming more efficient, scalable, and affordable thanks to ongoing developments in bioprocessing technologies, such as single-use systems, continuous manufacturing, and automation. These developments shorten production schedules and increase productivity, which propels market expansion.

A supportive regulatory environment is created by organizations like the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), which offer direction and assistance in the creation of vaccines and biopharmaceuticals. Accelerated approval processes, favorable regulations, and incentives all work to promote investment in technology and industrial facilities.

Increasing the Uses of Biotechnology: The development, manufacture, and discovery of vaccines and biopharmaceuticals all depend heavily on biotechnology. The creation of innovative treatments and vaccines for a variety of diseases is made possible by developments in genetic engineering, cell culture technology, and bioinformatics, which propels market growth.

Global Health Initiatives and Vaccination Programs: In order to prevent and manage infectious diseases, vaccination programs and global health initiatives are supported by public-private partnerships, international organizations, and government initiatives. These initiatives give biopharmaceutical and vaccine producers the chance to grow their product lines and penetrate new markets.

Pandemic Preparedness and Response: Situations like the COVID-19 pandemic emphasize the significance of having both quick response and preparedness measures in place. To address new infectious dangers, governments and healthcare institutions prioritize expenditures in vaccine development and production infrastructure, which drives demand in the market.

Growing Research and Development Expenditure: To find and create novel biopharmaceuticals and vaccines, pharmaceutical corporations, biotechnology businesses, and academic institutions devote a large amount of their resources to research and development (R&D). Innovation, pipeline development, and market growth are all fueled by R&D investments.

Growing Aging Population: As people age, they become more vulnerable to infectious and chronic illnesses, which increases the need for vaccinations and biopharmaceuticals. The market for therapeutic and preventive biologics is growing as the world's population ages.

Emerging Markets: The manufacturing of vaccines and biopharmaceuticals has enormous growth potential in emerging economies, especially those in Latin America and Asia-Pacific. Market expansion in these regions is driven by rising healthcare costs, bettering healthcare infrastructure, and an increase in the burden of disease.

Global Biopharmaceutical And Vaccine Production Market Restraints

Several factors can act as restraints or challenges for the Biopharmaceutical And Vaccine Production Market. These may include:

High Development and Production Costs: Research and development (R&D), production facilities, and equipment must be purchased up front in order to create and manufacture biopharmaceuticals and vaccines. Expensive expenses may prevent smaller businesses and startups from entering the market, which would reduce competition and innovation.

Complex Manufacturing Procedures: Cell culture, fermentation, and purification are only a few examples of the sophisticated biotechnological procedures used in the production of biopharmaceuticals and vaccines. In comparison to typical pharmaceuticals, these techniques have greater manufacturing costs and longer lead times since they need specialized tools, knowledge, and quality control procedures.

Regulatory Requirements and Compliance: Health authorities like the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) impose strict regulatory control on the manufacture of vaccines and biopharmaceuticals. For new products or production facilities in particular, meeting regulatory criteria for product quality, safety, and efficacy can be expensive and time-consuming.

Patent Protection and Intellectual Property Rights: The biopharmaceutical and vaccine industries are distinguished by robust patent protection and intellectual property rights. Patent exclusivity periods give innovative products market exclusivity, preventing generic or biosimilar competitors from undercutting them. On the other hand, heightened competition and declining prices for branded goods may result from patent expiration.

Supply Chain Vulnerabilities: Events like pandemics, natural catastrophes, and geopolitical unrest have the potential to disrupt the world's supply chain for the production of biopharmaceuticals and vaccines. Supply chain disruptions can result in shortages of vital supplies, machinery, and parts, which can impact output and product availability.

Market Access and Reimbursement Challenges: Due to distribution networks, healthcare infrastructure, and price and reimbursement policies, access to biopharmaceuticals and vaccines may be restricted in some areas. Adoption and uptake of innovative products can be impacted by market access issues, especially in developing economies where resources are scarce.

Technological Complexity and Innovation Risks: Technologies used in the manufacture of vaccines and biopharmaceuticals are always changing due to breakthroughs in purification methods, bioreactor design, and cell line development. There are inherent risks associated with investing in new technologies and innovation, such as scalability concerns, regulatory uncertainties, and technological difficulties.

Product Lifecycle Management: Pharmacovigilance, product stewardship, and post-market surveillance are continuous investments needed to manage the lifecycle of biopharmaceutical and vaccination products. Over the course of the product lifespan, expensive upgrades and revisions may be required due to changes in manufacturing procedures, regulatory requirements, or product formulas.

Safety and Quality Assurance: It is crucial for public health to guarantee the potency, safety, and purity of biopharmaceuticals and vaccinations. To maintain product quality, batch testing, validation processes, and quality control techniques are crucial.

Global Biopharmaceutical And Vaccine Production Market Segmentation Analysis

The Global Biopharmaceutical And Vaccine Production Market is Segmented on the basis of Product Type, Technology, Application, and Geography.

Biopharmaceutical And Vaccine Production Market, By Product Type

• Biopharmaceuticals: Includes therapeutic proteins (such as monoclonal antibodies, hormones, cytokines, and growth factors), vaccines, recombinant proteins, nucleic acid-based therapeutics (such as RNA and DNA vaccines), and cell-based therapies (such as stem cell therapies and CAR-T cell therapies).
• Vaccines: Includes prophylactic vaccines (for prevention of infectious diseases) and therapeutic vaccines (for treatment of diseases such as cancer and chronic infections).

Biopharmaceutical And Vaccine Production Market, By Technology

• Upstream Processing: Includes cell culture, fermentation, and cell expansion techniques for the production of biopharmaceuticals and vaccines in bioreactors or cell culture systems.
• Downstream Processing: Includes purification, separation, and recovery techniques for isolating and purifying biopharmaceuticals and vaccines from cell culture supernatants or fermentation broths.
• Single-Use Systems: Utilizes disposable bioprocessing equipment and consumables for biopharmaceutical and vaccine production, offering flexibility, scalability, and reduced risk of contamination.
• Continuous Manufacturing: Utilizes continuous bioprocessing techniques, such as perfusion cell culture and continuous chromatography, for more efficient and cost-effective production of biopharmaceuticals and vaccines compared to traditional batch processing.

Biopharmaceutical And Vaccine Production Market, By Application

• Infectious Diseases: Includes vaccines and therapeutics for prevention and treatment of infectious diseases such as influenza, COVID-19, hepatitis, human papillomavirus (HPV), and HIV/AIDS.
• Oncology: Includes biopharmaceuticals and vaccines for treatment of cancer, including monoclonal antibodies, cancer vaccines, and cell-based immunotherapies.
• Autoimmune Disorders: Includes biopharmaceuticals for treatment of autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and Crohn's disease.
• Metabolic Disorders: Includes biopharmaceuticals for treatment of metabolic disorders such as diabetes and obesity.
• Neurological Disorders: Includes biopharmaceuticals for treatment of neurological disorders such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis.
• Other Therapeutic Areas: Includes biopharmaceuticals and vaccines for treatment of cardiovascular diseases, respiratory diseases, rare diseases, and genetic disorders.

Biopharmaceutical And Vaccine Production Market, By Geography

• North America: Includes the United States and Canada, characterized by a strong biopharmaceutical industry, robust R&D infrastructure, and significant investments in vaccine development and production.
• Europe: Includes countries such as Germany, the UK, France, Italy, and Spain, with a well-established biopharmaceutical sector and leading vaccine manufacturers.
• Asia-Pacific: Includes China, Japan, India, South Korea, and Australia, where the biopharmaceutical and vaccine production market is rapidly expanding due to government initiatives, growing healthcare infrastructure, and increasing R&D investments.
• Latin America: Includes Brazil, Mexico, and other countries in Central and South America, with a growing demand for biopharmaceuticals and vaccines driven by population growth, disease burden, and government healthcare initiatives.
• Middle East and Africa: Includes countries such as Saudi Arabia, UAE, South Africa, and others, where the biopharmaceutical and vaccine production market is growing due to increasing healthcare expenditure, disease prevalence, and investments in pharmaceutical manufacturing.

Key Players

• The major players in the Biopharmaceutical And Vaccine Production Market are:
• F. Hoffmann-La Roche Ltd.
• Merck & Co. Inc.
• Johnson & Johnson
• Novartis International AG
• Pfizer Inc.
• Eli Lilly and Company
• Abbott Laboratories
• GlaxoSmithKline plc
• Amgen Inc.
• Sanofi S.A.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL BIOPHARMACEUTICAL AND VACCINE PRODUCTION MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL BIOPHARMACEUTICAL AND VACCINE PRODUCTION MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL BIOPHARMACEUTICAL AND VACCINE PRODUCTION MARKET, BY PRODUCT TYPE

• 5.1 Overview
• 5.2 Vaccine
• 5.3 Biopharmaceutical

6 GLOBAL BIOPHARMACEUTICAL AND VACCINE PRODUCTION MARKET, BY END-USE

• 6.1 Infectious Diseases
• 6.2 Oncology
• 6.3 Autoimmune Disorders
• 6.4 Metabolic Disorders

7 GLOBAL BIOPHARMACEUTICAL AND VACCINE PRODUCTION MARKET, BY TECHNOLOGY

• 7.1 Upstream Processing
• 7.2 Downstream Processing
• 7.3 Single-Use Systems
• 7.4 Continuous Manufacturing

8 GLOBAL BIOPHARMACEUTICAL AND VACCINE PRODUCTION MARKET: GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 The U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 The U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 The Middle East and Africa

9 GLOBAL BIOPHARMACEUTICAL AND VACCINE PRODUCTION MARKET: COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Novartis
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Pfizer
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Sanofi
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Roche
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Abbott
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Regeneron Pharmaceuticals
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.8 Alexion Pharmaceuticals
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.8 Johnson and Johnson
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.10 GlaxoSmithKline
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments
• 10.10 Merck
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 Appendix

• 11.1 Related Research